Psychedelic use and psychiatric risks.
HPPD
Psychedelics
Psychotic
Risks
Visual
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
24 Oct 2023
24 Oct 2023
Historique:
received:
14
04
2022
accepted:
07
10
2023
medline:
24
10
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
aheadofprint
Résumé
Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics. The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks. Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N=2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms. Among respondents who reported lifetime psychedelic use (n=613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders. Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.
Identifiants
pubmed: 37874345
doi: 10.1007/s00213-023-06478-5
pii: 10.1007/s00213-023-06478-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCCIH NIH HHS
ID : K23 AT010879
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
American Psychiatric Association (2013) Diagnostic and statistical manual of mental diseases (DSM-V), 5th edn. American Psychiatric Association Press, Washington, DC
doi: 10.1176/appi.books.9780890425596
Andersen KA, Carhart-Harris R, Nutt DJ, Erritzoe D (2021) Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand 143(2):101–118
doi: 10.1111/acps.13249
pubmed: 33125716
Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (2011) Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 114(1):61–67
doi: 10.1016/j.drugalcdep.2010.09.006
pubmed: 21035275
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402–1411
doi: 10.1056/NEJMoa2032994
pubmed: 33852780
Faul F, Erdfelder E, Buchner A, Lang AG (2009) Statistical power analyses using G* Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41(4):1149–1160
doi: 10.3758/BRM.41.4.1149
pubmed: 19897823
Galvão-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology 238(2):341–354
doi: 10.1007/s00213-020-05719-1
pubmed: 33427944
pmcid: 7826317
Gard DE, Pleet MM, Bradley ER, Penn AD, Gallenstein ML, Riley LS et al (2021) Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies. J Affect Disord Rep 6:100240
doi: 10.1016/j.jadr.2021.100240
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637–1648
doi: 10.1056/NEJMoa2206443
pubmed: 36322843
Halpern JH, Lerner AG, Passie T (2016) A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol 36. Springer, Berlin. https://doi.org/10.1007/7854_2016_457
doi: 10.1007/7854_2016_457
Halpern JH, Pope HG Jr (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 69(2):109–119
doi: 10.1016/S0376-8716(02)00306-X
pubmed: 12609692
Johnson MW, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603–620
doi: 10.1177/0269881108093587
pubmed: 18593734
pmcid: 3056407
Krebs TS, Johansen PØ (2013) Psychedelics and mental health: a population study. PLoS One 8(8):e63972
doi: 10.1371/journal.pone.0063972
pubmed: 23976938
pmcid: 3747247
Kuzenko N, Sareen J, Beesdo-Baum K, Perkonigg A, Höfler M, Simm J et al (2011) Associations between use of cocaine, amphetamines, or psychedelics and psychotic symptoms in a community sample. Acta Psychiatr Scand 123(6):466–474
doi: 10.1111/j.1600-0447.2010.01633.x
pubmed: 21054283
Lebedev AV, Acar K, Garzón B, Almeida R, Råback J, Åberg A et al (2021) Psychedelic drug use and schizotypy in young adults. Sci Rep 11(1):15058
doi: 10.1038/s41598-021-94421-z
pubmed: 34301969
pmcid: 8302700
Müller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y et al (2022) Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology 239(6):1933–1943
doi: 10.1007/s00213-022-06066-z
pubmed: 35076721
pmcid: 9166883
Roscoe J, Lozy O (2022) Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Sci Policy Law 8:20503245221085222
doi: 10.1177/20503245221085222
Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Pavlides JMW et al (2018) Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173(7):1705–1715
doi: 10.1016/j.cell.2018.05.046
pmcid: 6432650
Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ (2022) Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol 36(3):258–272
doi: 10.1177/02698811211069100
pubmed: 35107059
pmcid: 8905125
Simonsson O, Sexton JD, Hendricks PS (2021) Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol 35(4):447–452
doi: 10.1177/0269881121996863
pubmed: 33719688
pmcid: 8056715
Strassman RJ (1984) Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 172(10):577–595
doi: 10.1097/00005053-198410000-00001
pubmed: 6384428
von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K et al (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 56(101809)
Zimmerman M, Mattia JI (2001) A self-report scale to help make psychiatric diagnoses: the psychiatric diagnostic screening questionnaire. Arch Gen Psychiatry 58(8):787–794
doi: 10.1001/archpsyc.58.8.787
pubmed: 11483146